nancy lynn MD snyderman
CIK 1675198 · last filed 2026-08-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.75M
Companies
4
Total Filings
39
Lifetime Open-Market Net
-$2.14M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | 36,178 | $48.37 | $1.75M | -$2.23M | 20 | 2026-08-03 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 20 | $0.70 | $14 | $10.0K | 7 | 2025-05-16 |
| Axonics, Inc. (AXNX) Delisted | Director | 0 | $70.98 | $0 | $74.2K | 9 | 2024-11-15 |
| Future Health ESG Corp. (FHLTU) Delisted | Director | 22,512 | $11.15 | $251.0K | $0 | 2 | 2021-10-26 |
Recent Filings · Page 3 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-03 | ALKS | Mixed | +4,239 | -$29.6K | EDGAR |
| 2021-11-02 | Axonics, Inc. (AXNX) Delisted | Grant (A) | +2,261 | $0 | EDGAR |
| 2021-10-26 | Future Health ESG Corp. (FHLTU) Delisted | Disp (D) | −3,377 | $0 | EDGAR |
| 2021-09-16 | Future Health ESG Corp. (FHLTU) Delisted | Buy (P) | — | $0 | EDGAR |
| 2021-06-16 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2021-05-28 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | ALKS | Mixed | +4,700 | -$30.8K | EDGAR |
| 2020-12-17 | Lyra Therapeutics, Inc. (LYRA) Delisted | Buy (P) | +1,025 | $10.0K | EDGAR |
| 2020-12-04 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2020-10-29 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.